Laboratory Medicine ›› 2021, Vol. 36 ›› Issue (8): 823-827.DOI: 10.3969/j.issn.1673-8640.2021.08.009
Previous Articles Next Articles
QIAN Xiangbei1, WU Zhiming2
Received:
2020-12-14
Online:
2021-08-30
Published:
2021-08-30
CLC Number:
QIAN Xiangbei, WU Zhiming. Correlation of serum magnesium level with body composition and survival in hemodialysis patients[J]. Laboratory Medicine, 2021, 36(8): 823-827.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2021.08.009
组别 | 例数 | 性别 | 年龄/岁 | 糖尿病史/ [例(%)] | 透析时间/月 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
男/[例(%)] | 女/[例(%)] | |||||||||||||
低水平血镁组 | 70 | 47(67.1) | 23(32.9) | 74(65~82) | 30(42.9) | 26(7~60) | ||||||||
中水平血镁组 | 70 | 54(77.1) | 16(22.9) | 73(64~82) | 36(51.4) | 46(13~85) | ||||||||
高水平血镁组 | 70 | 44(62.9) | 26(37.1) | 67(59~78) | 24(34.3) | 72(9~133) | ||||||||
统计值 | 1.16 | 2.32 | 18.31 | 4.23 | 17.45 | |||||||||
P值 | 0.56 | 0.24 | 0.04 | 0.21 | 0.04 | |||||||||
组别 | 收缩压/kPa | 舒张压/kPa | β2-MG/(mg/L) | Hb/(g/L) | Alb/(g/L) | |||||||||
低水平血镁组 | 19.5±2.9 | 10.2±1.6 | 25.9(18.4~31.9) | 106(97~117) | 30(26~33) | |||||||||
中水平血镁组 | 19.7±2.8 | 10.1±1.7 | 25.2(21.0~28.9) | 109(100~118) | 32(29~34) | |||||||||
高水平血镁组 | 20.4±3.5 | 10.8±1.9 | 27.9(22.3~31.8) | 107(97~117) | 33(29~36) | |||||||||
统计值 | 4.31 | 3.82 | 1.16 | 6.21 | 15.39 | |||||||||
P值 | 0.21 | 0.09 | 0.18 | 0.46 | 0.04 | |||||||||
组别 | CRP/(mg/L) | 血清钙/(mg/L) | 磷酸盐/(mg/L) | 甲状旁腺激素/(pg/mL) | BMI/(kg/m2) | |||||||||
低水平血镁组 | 4.2(0.8~16.4) | 89(85~95) | 45 ± 15 | 116(69~208) | 22.0(17.8~23.2) | |||||||||
中水平血镁组 | 1.8(0.3~9.6) | 91(89~93) | 47 ± 15 | 119(71~193) | 22.9(18.6~26.0) | |||||||||
高水平血镁组 | 1.5(0.6~4.5) | 90(88~94) | 47 ± 14 | 115(46~183) | 21.4(17.8~24.0) | |||||||||
统计值 | 16.28 | 4.13 | 6.19 | 5.81 | 3.49 | |||||||||
P值 | 0.04 | 0.42 | 0.59 | 0.33 | 0.09 | |||||||||
组别 | 体细胞质量指数/(kg/m2) | 过度水合/L | 过度水合/细胞外 水分比值/% | 无脂组织指数/(kg/m2) | 脂肪组织指数/(kg/m2) | |||||||||
低水平血镁组 | 5.8(4.4~7.0) | 1.6(0.6~2.7) | 11.5(4.3~21.8) | 10.7(9.0~13.2) | 7.2(4.6~10.8) | |||||||||
中水平血镁组 | 6.2(5.0~8.3) | 0.7(0.2~1.8) | 4.7(1.1~14.0) | 11.4(9.8~14.2) | 8.6(6.4~11.2) | |||||||||
高水平血镁组 | 6.9(5.1~7.7) | 1.2(0.1~2.2) | 8.4(0.6~15.1) | 11.7(9.9~14.1) | 7.7(5.4~11.3) | |||||||||
统计值 | 19.21 | 20.15 | 1.29 | 1.62 | 3.20 | |||||||||
P值 | 0.04 | 0.04 | 0.42 | 0.59 | 0.33 |
组别 | 例数 | 性别 | 年龄/岁 | 糖尿病史/ [例(%)] | 透析时间/月 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
男/[例(%)] | 女/[例(%)] | |||||||||||||
低水平血镁组 | 70 | 47(67.1) | 23(32.9) | 74(65~82) | 30(42.9) | 26(7~60) | ||||||||
中水平血镁组 | 70 | 54(77.1) | 16(22.9) | 73(64~82) | 36(51.4) | 46(13~85) | ||||||||
高水平血镁组 | 70 | 44(62.9) | 26(37.1) | 67(59~78) | 24(34.3) | 72(9~133) | ||||||||
统计值 | 1.16 | 2.32 | 18.31 | 4.23 | 17.45 | |||||||||
P值 | 0.56 | 0.24 | 0.04 | 0.21 | 0.04 | |||||||||
组别 | 收缩压/kPa | 舒张压/kPa | β2-MG/(mg/L) | Hb/(g/L) | Alb/(g/L) | |||||||||
低水平血镁组 | 19.5±2.9 | 10.2±1.6 | 25.9(18.4~31.9) | 106(97~117) | 30(26~33) | |||||||||
中水平血镁组 | 19.7±2.8 | 10.1±1.7 | 25.2(21.0~28.9) | 109(100~118) | 32(29~34) | |||||||||
高水平血镁组 | 20.4±3.5 | 10.8±1.9 | 27.9(22.3~31.8) | 107(97~117) | 33(29~36) | |||||||||
统计值 | 4.31 | 3.82 | 1.16 | 6.21 | 15.39 | |||||||||
P值 | 0.21 | 0.09 | 0.18 | 0.46 | 0.04 | |||||||||
组别 | CRP/(mg/L) | 血清钙/(mg/L) | 磷酸盐/(mg/L) | 甲状旁腺激素/(pg/mL) | BMI/(kg/m2) | |||||||||
低水平血镁组 | 4.2(0.8~16.4) | 89(85~95) | 45 ± 15 | 116(69~208) | 22.0(17.8~23.2) | |||||||||
中水平血镁组 | 1.8(0.3~9.6) | 91(89~93) | 47 ± 15 | 119(71~193) | 22.9(18.6~26.0) | |||||||||
高水平血镁组 | 1.5(0.6~4.5) | 90(88~94) | 47 ± 14 | 115(46~183) | 21.4(17.8~24.0) | |||||||||
统计值 | 16.28 | 4.13 | 6.19 | 5.81 | 3.49 | |||||||||
P值 | 0.04 | 0.42 | 0.59 | 0.33 | 0.09 | |||||||||
组别 | 体细胞质量指数/(kg/m2) | 过度水合/L | 过度水合/细胞外 水分比值/% | 无脂组织指数/(kg/m2) | 脂肪组织指数/(kg/m2) | |||||||||
低水平血镁组 | 5.8(4.4~7.0) | 1.6(0.6~2.7) | 11.5(4.3~21.8) | 10.7(9.0~13.2) | 7.2(4.6~10.8) | |||||||||
中水平血镁组 | 6.2(5.0~8.3) | 0.7(0.2~1.8) | 4.7(1.1~14.0) | 11.4(9.8~14.2) | 8.6(6.4~11.2) | |||||||||
高水平血镁组 | 6.9(5.1~7.7) | 1.2(0.1~2.2) | 8.4(0.6~15.1) | 11.7(9.9~14.1) | 7.7(5.4~11.3) | |||||||||
统计值 | 19.21 | 20.15 | 1.29 | 1.62 | 3.20 | |||||||||
P值 | 0.04 | 0.04 | 0.42 | 0.59 | 0.33 |
项目 | 单因素分析 | 多因素分析 | |||||||
---|---|---|---|---|---|---|---|---|---|
模型1 | 模型2 | ||||||||
OR值 | 95%CI | P值 | OR值 | 95%CI | P值 | OR值 | 95%CI | P值 | |
年龄 | 1.05 | 1.02~1.07 | 0.04 | 1.02 | 0.93~1.08 | 0.74 | 1.01 | 0.97~1.05 | 0.47 |
透析时间 | 0.97 | 0.95~1.02 | 0.07 | 0.94 | 0.91~1.03 | 0.08 | 1.04 | 1.01~1.08 | 0.04 |
Alb | 0.44 | 0.27~0.82 | 0.04 | 0.62 | 0.31~1.38 | 0.33 | 0.75 | 0.46~1.15 | 0.69 |
体细胞质量指数 | 0.81 | 0.72~0.93 | 0.01 | 0.81 | 0.72~1.16 | 0.07 | 0.61 | 0.55~1.23 | 0.41 |
过度水合/细胞外水分比值 | 1.05 | 1.01~1.09 | 0.01 | 1.02 | 1.00~1.06 | 0.04 | 1.02 | 1.00~1.04 | 0.04 |
无脂组织指数 | 0.94 | 0.87~1.04 | 0.08 | ||||||
脂肪组织指数 | 0.88 | 0.82~1.05 | 0.13 |
项目 | 单因素分析 | 多因素分析 | |||||||
---|---|---|---|---|---|---|---|---|---|
模型1 | 模型2 | ||||||||
OR值 | 95%CI | P值 | OR值 | 95%CI | P值 | OR值 | 95%CI | P值 | |
年龄 | 1.05 | 1.02~1.07 | 0.04 | 1.02 | 0.93~1.08 | 0.74 | 1.01 | 0.97~1.05 | 0.47 |
透析时间 | 0.97 | 0.95~1.02 | 0.07 | 0.94 | 0.91~1.03 | 0.08 | 1.04 | 1.01~1.08 | 0.04 |
Alb | 0.44 | 0.27~0.82 | 0.04 | 0.62 | 0.31~1.38 | 0.33 | 0.75 | 0.46~1.15 | 0.69 |
体细胞质量指数 | 0.81 | 0.72~0.93 | 0.01 | 0.81 | 0.72~1.16 | 0.07 | 0.61 | 0.55~1.23 | 0.41 |
过度水合/细胞外水分比值 | 1.05 | 1.01~1.09 | 0.01 | 1.02 | 1.00~1.06 | 0.04 | 1.02 | 1.00~1.04 | 0.04 |
无脂组织指数 | 0.94 | 0.87~1.04 | 0.08 | ||||||
脂肪组织指数 | 0.88 | 0.82~1.05 | 0.13 |
项目 | 单因素分析 | 多因素分析 | |||||||
---|---|---|---|---|---|---|---|---|---|
模型1 | 模型2 | ||||||||
HR值 | 95%CI | P值 | HR值 | 95%CI | P值 | HR值 | 95%CI | P值 | |
低镁血症 | 1.78 | 1.12~3.10 | 0.007 | 1.73 | 1.08~2.92 | 0.009 | 1.71 | 1.04~2.52 | 0.01 |
透析时间 | 1.21 | 1.09~2.50 | 0.006 | 1.18 | 1.03~1.98 | 0.007 | 1.06 | 0.98~1.12 | 0.21 |
Alb | 1.69 | 1.47~1.85 | <0.0001 | 1.72 | 1.69~1.92 | <0.000 1 | 1.79 | 1.71~1.98 | 0.03 |
体细胞质量指数 | 0.98 | 0.85~1.13 | 0.71 | 0.92 | 0.78~1.06 | 0.38 | 0.89 | 0.75~1.12 | 0.10 |
过度水合/细胞外水分比值 | 1.03 | 0.91~1.05 | 0.05 | 1.01 | 0.96~1.02 | 0.45 | 1.02 | 0.96~1.04 | 0.77 |
项目 | 单因素分析 | 多因素分析 | |||||||
---|---|---|---|---|---|---|---|---|---|
模型1 | 模型2 | ||||||||
HR值 | 95%CI | P值 | HR值 | 95%CI | P值 | HR值 | 95%CI | P值 | |
低镁血症 | 1.78 | 1.12~3.10 | 0.007 | 1.73 | 1.08~2.92 | 0.009 | 1.71 | 1.04~2.52 | 0.01 |
透析时间 | 1.21 | 1.09~2.50 | 0.006 | 1.18 | 1.03~1.98 | 0.007 | 1.06 | 0.98~1.12 | 0.21 |
Alb | 1.69 | 1.47~1.85 | <0.0001 | 1.72 | 1.69~1.92 | <0.000 1 | 1.79 | 1.71~1.98 | 0.03 |
体细胞质量指数 | 0.98 | 0.85~1.13 | 0.71 | 0.92 | 0.78~1.06 | 0.38 | 0.89 | 0.75~1.12 | 0.10 |
过度水合/细胞外水分比值 | 1.03 | 0.91~1.05 | 0.05 | 1.01 | 0.96~1.02 | 0.45 | 1.02 | 0.96~1.04 | 0.77 |
[1] |
JAHNEN-DECHENT W, KETTELER M. Magnesium basics[J]. Clin Kidney J, 2012, 5(Suppl 1):i3-i14.
DOI URL |
[2] |
LIU M, YANG H, MAO Y. Magnesium and liver disease[J]. Ann Transl Med, 2019, 7(20):578.
DOI URL |
[3] |
CUNNINGHAM J, RODRÍGUEZ M, MESSA P. Magnesium in chronic kidney disease Stages 3 and 4 and in dialysis patients[J]. Clin Kidney J, 2012, 5(Suppl 1):i39-i51.
DOI URL |
[4] |
LEENDERS N H J, VAN ITTERSUM F J, HOEKSTRA T, et al. Routine hemodialysis induces a decline in plasma magnesium concentration in most patients:a prospective observational cohort study[J]. Sci Rep, 2018, 8(1):10256.
DOI URL |
[5] |
KANBAY M, YILMAZ M I, APETRII M, et al. Relationship between serum magnesium levels and cardiovascular events in chronic kidney disease patients[J]. Am J Nephrol, 2012, 36(3):228-237.
DOI URL |
[6] | 顾峰. 维持性血液透析患者心血管疾病死亡的危险因素分析[J]. 检验医学, 2017, 32(6):486-489. |
[7] |
LACSON E Jr, WANG W, MA L, et al. Serum magnesium and mortality in hemodialysis patients in the United States:a cohort study[J]. Am J Kidney Dis, 2015, 66(6):1056-1066.
DOI URL |
[8] |
WU L, CAI K, LUO Q, et al. Baseline serum magnesium level and its variability in maintenance hemodialysis patients:associations with mortality[J]. Kidney Blood Press Res, 2019, 44(2):222-232.
DOI URL |
[9] |
LI G, ZHANG L, REN H, et al. Clearance of magnesium in peritoneal dialysis patients:a single-center study[J]. Blood Purif, 2019, 47(Suppl 1):1-7.
DOI URL |
[10] | SHIMOHATA H, YAMASHITA M, OHGI K, et al. The relationship between serum magnesium levels and mortality in non-diabetic hemodialysis patients:a 10-year follow-up study[J]. Hemodial Int, 2019, 23(3):369-374. |
[11] | 朱安友, 王凤超, 陈卫东, 等. 肾功能损伤及血液透析患者血清胃蛋白酶原浓度的变化[J]. 检验医学, 2014, 29(6):685-687. |
[12] |
YU L, LI H, WANG S X. Serum magnesium and mortality in maintenance hemodialysis patients[J]. Blood Purif, 2017, 43(1-3):31-36.
DOI URL |
[13] | 蒋小红, 吕旭军, 许德顺. 铁代谢与慢性肾功能衰竭的关系[J]. 检验医学, 2010, 25(5):391-392. |
[14] |
NIJENHUIS T, HOENDEROP J G, BINDELS R J. Downregulation of Ca(2+) and Mg(2+) transport proteins in the kidney explains tacrolimus(FK506)-induced hypercalciuria and hypomagnesemia[J]. J Am Soc Nephrol, 2014, 15(3):549-557.
DOI URL |
[15] |
COSTA A, TEJPAR S, PRENEN H, et al. Hypomagnesaemia and targeted anti-epidermal growth factor receptor(EGFR) agents[J]. Target Oncol, 2011, 6(4):227-233.
DOI URL |
[16] |
FATUZZO P, PORTALE G, SCOLLO V, et al. Proton pump inhibitors and symptomatic hypomagnesemic hypoparathyroidism[J]. J Nephrol, 2017, 30(2):297-301.
DOI URL |
[17] | CHEN W, FITZPATRICK J, MONROY-TRUJILLO J M, et al. Diabetes mellitus modifies the associations of serum magnesium concentration with arterial calcification and stiffness in incident hemodialysis patients[J]. Kidney Int Rep, 2019, 4(6):806-813. |
[18] |
YANG X, SOOHOO M, STREJA E, et al. Serum magnesium levels and hospitalization and mortality in incident peritoneal dialysis patients:a cohort study[J]. Am J Kidney Dis, 2016, 68(4):619-627.
DOI URL |
[19] |
JOFFRES M R, REED D M, YANO K. Relationship of magnesium intake and other dietary factors to blood pressure:the Honolulu heart study[J]. Am J Clin Nutr, 1987, 45(2):469-475.
DOI URL |
[20] |
ALHOSAINI M, WALTER J S, SINGH S, et al. Hypomagnesemia in hemodialysis patients:role of proton pump inhibitors[J]. Am J Nephrol, 2014, 39(3):204-209.
DOI URL |
[21] |
FERRÈ S, LI X, ADAMS-HUET B, et al. Association of serum magnesium with all-cause mortality in patients with and without chronic kidney disease in the Dallas Heart Study[J]. Nephrol Dial Transplant, 2018, 33(8):1389-1396.
DOI URL |
[22] |
MIZUIRI S, NISHIZAWA Y, YAMASHITA K, et al. Hypomagnesemia is not an independent risk factor for mortality in Japanese maintenance hemodialysis patients[J]. Int Urol Nephrol, 2019, 51(6):1043-1052.
DOI URL |
[23] |
TAMURA T, UNAGAMI K, OKAZAKI M, et al. Serum magnesium levels and mortality in Japanese maintenance hemodialysis patients[J]. Blood Purif, 2019, 47(Suppl 2):88-94.
DOI URL |
[24] |
OKUSANYA B O, OLADAPO O T, LONG Q, et al. Clinical pharmacokinetic properties of magnesium sulphate in women with pre-eclampsia and eclampsia[J]. BJOG, 2016, 123(3):356-366.
DOI URL |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||